Research Article

IncRNA ROR and miR-125b Predict the Prognosis in Heart Failure Combined Acute Renal Failure

Qianlong Xue,1 Lipeng Yang,1 Jia Wang,1 Linlin Li,1 Hui Wang,1 and Ying He2

1Department of Emergency Medicine, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China
2Department of Gynecology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China

Correspondence should be addressed to Ying He; heying@bjtu.edu.cn

Received 15 October 2021; Accepted 20 December 2021; Published 20 January 2022

Academic Editor: Francesco Busardò

Copyright © 2022 Qianlong Xue et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To elucidate the correlation between expression levels of long noncoding RNA (IncRNA) ROR and microRNA-125b (miR-125b) with the prognosis in heart failure (HF) patients combined acute renal failure (ARF).

Methods. HF patients combined ARF (n = 90) and healthy controls (n = 90) in the same period were included in our hospital from April 2016 to December 2018. Every subject was followed up for 24 months. Serum levels of IncRNA ROR and miR-125b were detected, and their expression correlation was analyzed by Pearson correlation test. Receiver operating characteristic (ROC) curves were depicted for assessing the sensitivity and specificity of IncRNA ROR and miR-125b in diagnosing HF combined ARF.

Results. IncRNA ROR was upregulated in serum of HF patients combined ARF, and its level was positively correlated to NYHA classification. miR-125b displayed an opposite trend. In serum samples of HF combined ARF, expression level of IncRNA ROR was negatively related to that of miR-125b. Diagnostic potentials of IncRNA ROR and miR-125b in HF combined ARF were confirmed by ROC curve analyses (IncRNA ROR: AUC = 0.9199, cutoff value = 5.595, sensitivity = 92.22%, and specificity = 73.33%; miR-125b: AUC = 0.8509, cutoff value = 2.290, sensitivity = 81.11%, and specificity = 74.44%). After 2-year follow-up, 16 cases were dead. Higher incidences of death and rehospitalization were observed in HF combined ARF cases expressing higher serum level of IncRNA ROR or lower level of miR-125b.

Conclusions. Serum level of IncRNA ROR is upregulated, and miR-125b is downregulated in HF patients combined ARF. Their levels are linked to NYHA classification, which can be utilized as prognostic biomarkers in HF combined ARF.

1. Introduction

Heart failure (HF) is caused by increased cardiac load and dyscirculatory syndrome owing to systolic and diastolic dysfunctions. As the heart disease worsens, insufficient blood perfusion and renal blood stasis impairs renal function [1]. Acute renal failure (ARF) is a clinical syndrome of rapid decline of glomerular filtration function, imbalance of water and electrolyte, and accumulation of nitrogen wastes in the body in a short period of time [2]. Clinically, HF patients are prone to develop ARF. ARF-induced water retention seriously continues to aggravate HF, thus increasing treatment difficulty [3].

Long noncoding RNAs (lncRNAs) are functional RNAs with over 200 nt long. They are generally transcribed in eukaryotes and unable to encode proteins [4]. Initially, lncRNAs were considered as byproducts of RNA polymerase II transcription without biological functions. Later, accumulating evidences have proven the vital functions in genomic imprinting, chromatin modification, transcriptional activation, and nuclear transportation at multiple levels [5]. In recent years, lncRNAs are reported as important regulators in HF [6]. Further, IncRNA ZNF593-AS alleviates contractile dysfunction in dilated cardiomyopathy [7]. And IncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin [8]. IncRNA ROR, H19 is downregulated in human chromosome 18q21.31 containing 4 exons [9]. Numerous previous studies have demonstrated the vital role of ROR in cardiovascular diseases. It is reported that IncRNA ROR is upregulated in in vitro cultured hypertrophic cardiomyocytes, which deteriorates myocardial hypertrophy into cardiac hypertrophy and even HF [10]. Further, the ROR/miR-124-3p/TRAF6 axis...
regulated the ischemia reperfusion injury-induced inflammatory response in human cardiomyocytes [11]. Besides, overexpressed ROR promotes the biological characteristics of ox-LDL-induced HUVECs let-7b-5p/HOXA1 axis in ath-erosclerosis [12]. However, the importance of ROR in HF patients was unknown.

MicroRNAs (miRNAs) are endogenous, single-strand RNAs containing 22 nucleotides. Through complementary base pairing, miRNAs posttranscriptionally regulate target gene expressions [13]. miRNAs are extensively involved in cardiac pathophysiological process, including cardiac development, cardiac hypertrophy, myocardial ischemia, and HF [14–16]. The miR-125 family is highly conserved in mammals and participates in embryogenesis, immune response, tumorrogenesis, and ischemia reperfusion injury [17, 18].

miR-125b is transcribed on chromosome 11q23 (has-miR-125b-1) and 21q21 (has-miR-125b-2) [19]. Busk and Cirera [20] suggested that miR-125b is downregulated in HF patients. Further, miR-125b is critical for fibroblast-to-myoﬁbroblast transition and cardiac ﬁbrosis [21]. In addition, hypoxia-elicited mesenchymal stem cell-derived exosomes facilitate cardiac repair through miR-125b-mediated prevention of cell death in myocardial infarction [22]. However, the role of miR-125b in heart failure was unclear. In this paper, we aim to uncover the prognostic potentials of IncRNA ROR and miR-125b in HF patients combined ARF.

2. Patients and Methods

2.1. Baseline Characteristics. A total of 90 HF patients combined ARF treated in our hospital from April 2016 to December 2018 were included. Based on the New York Heart Association (NYHA) functional classiﬁcation, there were 0 case in class I, 30 in class II, 32 in class III, and 28 in class IV included in multiple groups was done using one-way ANOVA test followed by post hoc test (least signiﬁcant difference). Pearson correlation test was applied for assessing the relationship between serum levels of IncRNA ROR and miR-125b. Diagnostic potentials were assessed by depicting receiver operating characteristic (ROC) curves. p < 0.05 indicated the significant difference.

3. Results

3.1. Baseline Characteristics of Subjects. Through analyzing clinical data of subjects, no signiﬁcant differences were found in age, sex, and BMI between healthy subjects and HF patients combined ARF (Table 1). Baseline characteristics of them were comparable.

3.2. Serum Levels of IncRNA ROR and miR-125b. Compared with healthy subjects, serum level of IncRNA ROR was upregulated in HF patients combined ARF (Figure 1(a)), while miR-125b level was downregulated (Figure 1(b)).

3.3. Correlation between Serum Levels of IncRNA ROR and miR-125b with NYHA. There were 0 case in NYHA class I, 30 in class II, 32 in class III, and 28 in class IV included in this trial. Interestingly, serum level of IncRNA ROR gradually increased with NYHA worsening in HF patients combined ARF (Figure 2(a)). Conversely, miR-125b level

| Variable               | Control         | HF combined ARF | p    |
|------------------------|-----------------|-----------------|------|
| Age                    | 62.13 ± 6.75    | 60.93 ± 5.85    | 0.204|
| Sex (male/female)      | 45/45           | 45/45           | N.S. |
| BMI (kg/m²)            | 22.62 ± 3.11    | 22.73 ± 3.51    | 0.824|

HF: heart failure; ARF: acute renal failure; BMI: body mass index; N.S.: no significant difference.
showed the opposite trend (Figure 2(b)). It is believed that high level of lncRNA ROR and low level of miR-125b aggravated the development of HF.

3.4. Correlation between Serum Levels of lncRNA ROR and miR-125b. Pearson correlation test uncovered a negative link between serum levels of lncRNA ROR and miR-125b in HF patients combined ARF (Figure 3).

Figure 1: Serum levels of lncRNA ROR and miR-125b. Serum levels of (a) lncRNA ROR and (b) miR-125b in healthy subjects and heart failure patients combined acute renal failure.

Figure 2: Correlation between serum levels of lncRNA ROR and miR-125b with NYHA. Serum levels of (a) lncRNA ROR and (b) miR-125b in heart failure patients combined acute renal failure with NYHA classes II, III, and IV.

Figure 3: Correlation between serum levels of lncRNA ROR and miR-125b. A negative link between serum levels of lncRNA ROR and miR-125b in heart failure patients combined acute renal failure.

3.5. Diagnostic Potentials of lncRNA ROR and miR-125b in HF Combined ARF. ROC curves were depicted for assessing the potentials of lncRNA ROR and miR-125b as diagnostic biomarkers in HF combined ARF. As the data revealed, lncRNA ROR and miR-125b were qualified in diagnosing HF combined ARF (lncRNA ROR: AUC = 0.9199, cutoff value = 5.595, sensitivity = 92.22%, and specificity = 73.33%; miR-125b: AUC = 0.8509, cutoff value = 2.290, sensitivity = 81.11%, and specificity = 74.44%) (Figures 4(a) and 4(b)).

3.6. Correlation between Serum Levels of lncRNA ROR and miR-125b with Prognosis in HF Combined ARF. Based on the mentioned cutoff value of lncRNA ROR, included patients were assigned into two groups. After 2-year follow-up, 16 cases were dead. Higher incidences of death and rehospitalization were observed in HF combined ARF cases expressing higher serum level of lncRNA ROR. In a similar way, patients were assigned into two groups according to the cutoff value of miR-125b. HF patients combined ARF expressing lower level of miR-125b had higher incidences of death and rehospitalization (Table 2).

4. Discussion

Renal insufficiency secondary to HF is commonly seen and its mortality is high [23]. ARF is a key factor in determining the progression and prognosis of HF [24]. Recently, biomarkers of impaired renal function have been identified as
risk factors for HF, displaying a predictive value for poor, long-term prognosis [25].

Critical functions of lncRNAs have been highlighted [26, 27]. Yang et al. [28] discovered differentially expressed lncRNAs between ischemic HF patients and nonischemic HF ones by RNA-seq. It is reported that lncRNA Mhrt 779 antagonizes the development of cardiac hypertrophy and HF in mice induced by aortic contraction [29]. miRNAs are highly conserved in different species and tissue-specific. Primary transcripts are cleaved into pre-miRNAs and then translocate into nuclei to form mature miRNAs [30, 31]. About 30% of human genomes can be regulated by miRNAs [9]. Scrutinio et al. [32] found downregulated miR-150-5p in advanced HF patients, which is linked to cardiac remodeling, disease severity, and prognosis. To uncover the role of ROR and miR-125b, compared to previous research, we found that lncRNA ROR was upregulated in serum of HF patients combined ARF; however, miR-125b was found to be downregulated in serum of HF combined ARF. Further, ROR increased as disease stage advanced while miR-125b showed an opposite phenotype. The previous findings indicated the potential relation between ROR and miR-125b in HF combined ARF. lncRNA-miRNA interaction contributes to cell phenotype regulations [33]. Through absorbing miRNAs as ceRNAs, lncRNAs inhibit miRNA expressions [34]. Besides, lncRNAs are precursors of miRNAs through intracellular cleavage [35]. GAS5 is downregulated in fibrotic cardiac tissues, which alleviates HF by negatively regulating miR-21 [36]. Upregulated HOTAIR may be a biomarker of HF [37]. HOTAIR regulates phosphatase and tensin homologue expressions in HF by competing with miR-19 [38]. Through Pearson correlation test, we found that lncRNA ROR was negatively linked to miR-125b in serum of HF patients combined ARF.

Circulating lncRNA could act as a prognostic factor for disease. In previous study, NEAT1 was reported as an unfavorable prognostic factor in chronic heart failure patients by log-rank test and ROC analysis [39]. Further, Chen et al. also found that NEAT1 was an unfavorable factor in acute ST-segment elevation myocardial infarction by ROC analysis [40]. In our research, we found that ROR and miR-125b were prognostic factors by ROC analysis.

However, there are still limitations in our research. This research only detected the level of ROR and miR-125b in clinical samples; thus, the in vivo and in vitro assays should be conducted to further explore the relationship of ROR and miR-125b and HF. Moreover, their diagnostic and prognostic potentials in HF combined ARF were identified as well.

5. Conclusions

Serum level of lncRNA ROR is upregulated, and miR-125b is downregulated in HF patients combined ARF. Their levels are linked to NYHA classification, which can be utilized as prognostic biomarkers in HF combined ARF.
Data Availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declared no conflict of interest.

References

[1] Z. F. Zhu, J. J. Li, J. Liu et al., ”Circulating Th17 cells are not elevated in patients with chronic heart failure,” Scandinavian Cardiovascular Journal, vol. 46, no. 5, pp. 295–300, 2012.

[2] S. Shrivastava, N. Srivastava, and M. Alfanso-Jaume, ”Acute renal failure with cocaine and SGLT-2 inhibitor,” American Journal of Therapeutics, vol. 26, no. 6, pp. e762–e763, 2019.

[3] O. Kawarada, S. Yasuda, T. Noguchi, T. Anzai, and H. Ogawa, ”Renovascular heart failure: heart failure in patients with ath erosclerotic renal artery disease,” Cardiovascular Intervention and Therapeutics, vol. 31, no. 3, pp. 171–182, 2016.

[4] Y. B. Meng, X. He, Y. F. Huang, Y. F. Huang, Q. N. Wu, Y. C. Zhou, and D. J. Hao, ”Long noncoding RNA CRNDE promotes multiple myeloma cell growth by suppressing miR-451,” Oncology Research, vol. 25, no. 7, pp. 1207–1214, 2017.

[5] M. Sun and W. L. Kraus, ”From discovery to function: the expanding role of long noncoding RNAs in physiology and disease,” Endocrine Reviews, vol. 36, no. 1, pp. 25–64, 2015.

[6] R. Kumarswamy, C. Bauters, I. Volkmann et al., ”Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure,” Circulation Research, vol. 114, no. 10, pp. 1569–1575, 2014.

[7] J. Fan, H. Li, R. Xie et al., ”LncRNA ZNF593-AS alleviates contractile dysfunction in diluted cardiomyopathy,” Circulation Research, vol. 128, no. 11, pp. 1708–1723, 2021.

[8] Y. Zhang, Y. Li, Q. Hu et al., ”The IncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin,” Nature Cell Biology, vol. 22, no. 11, pp. 1332–1345, 2020.

[9] H. Chen and X. Li, ”LncRNA ROR is involved in cerebral hypoxia/reoxygenation-induced injury in PC12 cells via regulating miR-135a-5p/ROCK1/2,” American Journal of Translational Research, vol. 11, no. 9, pp. 6145–6158, 2019.

[10] F. Gorzin, A. A. Amirzargar, M. J. Mahmoudi et al., ”FOXP3, RORyt and IL-10 cytokine profile in chronic heart failure,” Bratislavské Lekárske Listy, vol. 118, no. 10, pp. 637–641, 2017.

[11] Y. P. Liang, Q. Liu, G. H. Xu et al., ”The IncRNA ROR/ miR-124-3p/TRAF6 axis regulates the ischemia reperfusion injury-induced inflammatory response in human cardiac myocytes,” Journal of Bioenergetics and Biomembranes, vol. 51, no. 6, pp. 381–392, 2019.

[12] C. Yu, B. Wu, J. Jiang, G. Yang, C. Weng, and F. Cai, ”Overexpressed IncRNA ROR promotes the biological characteristics of ox-LDL-induced HUVECs via the let-7b-5p/HOXA1 axis in atherosclerosis,” Frontiers in Cardiovascular Medicine, vol. 8, article 659769, 2021.

[13] J. Krol, I. Loedige, and W. Filipowicz, ”The widespread regulation of microRNA biogenesis, function and decay,” Nature Reviews Genetics, vol. 11, no. 9, pp. 597–610, 2010.

[14] J. X. Wang, X. J. Zhang, Q. Li et al., ”MicroRNA-103/107 regulate programmed necrosis and myocardial ischemia/reperfu-

dion injury through targeting FADD,” Circulation Research, vol. 117, no. 4, pp. 352–363, 2015.

[15] Q. Su, L. Li, J. Zhao, Y. Sun, and H. Yang, ”MiRNA expression profile of the myocardial tissue of pigs with coronary micro-

embolization,” Cellular Physiology and Biochemistry, vol. 43, no. 3, pp. 1012–1024, 2017.

[16] J. S. Lee, D. K. Yang, J. H. Park et al., ”MicroRNA-101b attenuates cardiomyocyte hypertrophy by inhibiting protein kinase C epsilon signaling,” FEBS Letters, vol. 591, no. 1, pp. 16–27, 2017.

[17] K. H. Kim, Y. M. Seo, E. Y. Kim et al., ”The miR-125 family is an important regulator of the expression and maintenance of maternal effect genes during preimplantational embryo develop-

ment,” Open Biology, vol. 6, no. 11, article 160181, 2016.

[18] X. Wang, T. Ha, J. Zou et al., ”MicroRNA-125b protects against myocardial ischaemia/reperfusion injury via targeting p53-mediated apoptotic signalling and TRAF6,” Cardiovascu-

lar Research, vol. 102, no. 3, pp. 385–395, 2014.

[19] A. Rodriguez, S. Griffiths-Jones, J. L. Ashurst, and A. Bradley, ”Identification of mammalian microRNA host genes and transcrip-

tion units,” Genome Research, vol. 14, no. 10A, pp. 1902–1910, 2004.

[20] P. K. Busk and S. Cirera, ”MicroRNA profiling in early hyper-

trophic growth of the left ventricle in rats,” Biochemical and Biophysical Research Communications, vol. 396, no. 4, pp. 989–993, 2010.

[21] V. Nagpal, R. Rai, A. T. Place et al., ”miR-125b is critical for fibroblast-to-myofibroblast transition and cardiac fibrosis,” Circulation, vol. 133, no. 3, pp. 291–301, 2016.

[22] L. P. Zhu, T. Tian, J. Y. Wang et al., ”Hypoxia-elicited mesenchymal stem cell-derived exosomes facilitates cardiac repair through miR-125b-mediated prevention of cell death in myocardial infarction,” Theranostics, vol. 8, no. 22, pp. 6163–6177, 2018.

[23] M. Metra, G. Cotter, M. Gheorghiade, C. L. Dei, and A. A. Voors, ”The role of the kidney in heart failure,” European Heart Journal, vol. 33, no. 17, pp. 2135–2142, 2012.

[24] S. Ather, W. Chan, B. Bozkurt et al., ”Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction,” Journal of the American College of Cardiology, vol. 59, no. 11, pp. 998–1005, 2012.

[25] D. L. Dries, D. V. Exner, M. J. Domanski, B. Greenberg, and L. W. Stevenson, ”The prognostic implications of renal insuffi-

ciency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction,” Journal of the American College of Cardiology, vol. 35, no. 3, pp. 681–689, 2000.

[26] R. B. Lanz, N. J. McKenna, S. A. Onate et al., ”A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex,” Cell, vol. 97, no. 1, pp. 17–27, 1999.

[27] C. A. Klatenhoff, J. C. Scheuermann, L. E. Surface et al., ”Braveheart, a long noncoding RNA required for cardiovascular lineage commitment,” Cell, vol. 152, no. 3, pp. 570–583, 2013.

[28] K. C. Yang, K. A. Yamada, A. Y. Patel et al., ”Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support,” Circulation, vol. 129, no. 9, pp. 1009–1021, 2014.

[29] C. Wu, and P. Arora, ”Long noncoding MhrtRNA,” Circula-

tion. Cardiovascular Genetics, vol. 8, no. 1, pp. 213–215, 2015.
[30] A. E. Pasquinelli, B. J. Reinhart, F. Slack et al., “Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA,” Nature, vol. 408, no. 6808, pp. 86–89, 2000.
[31] D. P. Bartel, "MicroRNAs: genomics, biogenesis, mechanism, and function," Cell, vol. 116, no. 2, pp. 281–297, 2004.
[32] D. Scrutinio, F. Conserva, A. Passantino, M. Iacoviello, R. Lagioia, and L. Gesualdo, “Circulating microRNA-150-5p as a novel biomarker for advanced heart failure: a genome-wide prospective study,” The Journal of Heart and Lung Transplantation, vol. 36, no. 6, pp. 616–624, 2017.
[33] Y. Huang, "The novel regulatory role of IncRNA-miRNA-mRNA axis in cardiovascular diseases," Journal of Cellular and Molecular Medicine, vol. 22, no. 12, pp. 5768–5775, 2018.
[34] Q. Zhou, Q. Yu, Y. Gong et al., "Construction of a IncRNA-miRNA-mRNA network to determine the regulatory roles of IncRNAs in psoriasis," Experimental and Therapeutic Medicine, vol. 18, no. 5, pp. 4011–4021, 2019.
[35] L. He, Y. Chen, S. Hao, and J. Qian, “Uncovering novel landscape of cardiovascular diseases and therapeutic targets for cardioprotection via long noncoding RNA-miRNA-mRNA axes,” Epigenomics-Uk, vol. 10, no. 5, pp. 661–671, 2018.
[36] H. Tao, J. G. Zhang, R. H. Qin et al., “LncRNA GAS5 controls cardiac fibroblast activation and fibrosis by targeting miR-21 via PTEN/MMP-2 signaling pathway," Toxicology, vol. 386, pp. 11–18, 2017.
[37] S. Greco, G. Zaccagnini, A. Perfetti et al., “Long noncoding RNA dysregulation in ischemic heart failure,” Journal of Translational Medicine, vol. 14, no. 1, p. 183, 2016.
[38] Y. Lai, S. He, L. Ma et al., “HOTAIR functions as a competing endogenous RNA to regulate PTEN expression by inhibiting miR-19 in cardiac hypertrophy," Molecular and Cellular Biochemistry, vol. 432, no. 1-2, pp. 179–187, 2017.
[39] H. Zhang, N. Zhang, W. Jiang, and X. Lun, “Clinical significance of the long non-coding RNA NEAT1/miR-129-5p axis in the diagnosis and prognosis for patients with chronic heart failure," Experimental and Therapeutic Medicine, vol. 21, no. 5, p. 512, 2021.
[40] Z. Chen, Y. Yan, J. Wu, C. Qi, J. Liu, and J. Wang, "Expression level and diagnostic value of exosomalNEAT1/miR-204/MMP-9 in acuteST-segment elevation myocardial infarction," IUBMB Life, vol. 72, no. 11, pp. 2499–2507, 2020.